Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ib study of genolimzumab in combination with fruquintinib in the selected tumor types

Trial Profile

A phase Ib study of genolimzumab in combination with fruquintinib in the selected tumor types

Planning
Phase of Trial: Phase I

Latest Information Update: 03 Dec 2018

At a glance

  • Drugs Fruquintinib (Primary) ; Genolimzumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Dec 2018 New trial record
    • 29 Oct 2018 According to a Genor Biopharma media release, the study is expected to begin enrolling patients in China in late 2018. Data from this study may lead to subsequent Phase III registration studies to establish the safety and efficacy of the combination in China.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top